Arizona Isotope Science Research Corporation (AZI) specializes in the development and production of a diverse range of medical isotopes that are crucial for nuclear medicine applications. The company focuses on producing isotopes such as Actinium-225, which is utilized in targeted alpha therapy for various cancers, including prostate and brain cancers. Additionally, AZI produces Cerium-134, which aids in disease diagnosis and treatment monitoring, and Cesium-131, known for its effectiveness in treating solid tumors by delivering localized radiation while minimizing exposure to surrounding healthy tissues. Other isotopes produced include Cobalt-57, used for calibrating medical equipment, and Germanium-68, which has applications in cancer treatment and diagnostic imaging.

The company also emphasizes the importance of Iodine-123, which has become the preferred choice for diagnostic radiopharmaceuticals due to its lower radiation dose to patients compared to Iodine-131. This isotope is particularly valuable for thyroid imaging. Furthermore, AZI produces Strontium-82, which is essential for generating Rubidium-82, a key agent in Positron Emission Tomography (PET) for myocardial perfusion imaging. Overall, AZI's commitment to advancing nuclear medicine through the production of these isotopes plays a significant role in enhancing diagnostic and therapeutic options in the medical field.

United States

Arizona Isotope Science Research Corporation (AZI), was formed in 2017 and specializes in nuclear medicine and the production of isotopes that are beneficial to medical research and treatment.

Arizona Isotope Science Research Corp.

Company Details